- Motley Fool
Why Weight Loss Drug Developer Stocks Tumbled on Thursday
Companies like Novo Nordisk and Eli Lilly might soon have a determined competitor in their hottest product category.
- Investor's Business Daily
AstraZeneca Says It Has A 'Powerful' — And Differentiated — Approach To Obesity Treatment
AstraZeneca stock skidded Thursday despite strong quarterly sales as an FDA panel met to discuss its lung cancer treatment.
- Zacks
Roche (RHHBY) Sales, Earnings Grow in 1H24, '24 EPS View Raised
Roche (RHHBY) records impressive second-quarter and first-half 2024 performance on the back of strong demand for drugs and tests. Consequently, the company raises its annual earnings guidance.
